Stephens Reiterates Overweight Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “overweight” rating reiterated by research analysts at Stephens in a report issued on Thursday,Benzinga reports. They currently have a $33.00 price target on the biopharmaceutical company’s stock. Stephens’ price objective indicates a potential upside of 44.17% from the company’s current price.

A number of other research firms also recently weighed in on CPRX. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Trading Up 5.7 %

Shares of CPRX stock opened at $22.89 on Thursday. The company has a market capitalization of $2.73 billion, a P/E ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals has a 12 month low of $14.47 and a 12 month high of $24.64. The stock has a 50 day moving average of $22.21 and a two-hundred day moving average of $21.40.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Creative Planning boosted its holdings in Catalyst Pharmaceuticals by 26.9% in the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,699 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Catalyst Pharmaceuticals by 11.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 1,989 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in shares of Catalyst Pharmaceuticals by 48.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company’s stock valued at $3,532,000 after purchasing an additional 60,000 shares during the last quarter. Summit Global Investments grew its position in shares of Catalyst Pharmaceuticals by 2.6% during the 3rd quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock worth $1,537,000 after buying an additional 1,923 shares during the period. Finally, CWA Asset Management Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth approximately $534,000. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.